Aviceda Therapeutics
Cambridge, MA, USA
Aviceda Therapeutics is a private clinical-stage biotech company focused on the next generation of glyco-immune therapeutics that leverage the Glyco-Code® technology platform to address inflammatory diseases of the innate immune system including geographic atrophy (GA) from age-related macular degeneration (AMD), cancer, fibrosis, neurologic diseases, and others. At Aviceda, we exploit a unique family of receptors expressed on all innate immune cells, and their associated glycobiological interactions, to develop transformative medicines for a variety of pathologies with current unmet needs. We combine the power of our biology with our innovative cell-based high-throughput screening platform and proprietary nanoparticle technology to modulate the immune response specifically and profoundly. Aviceda has assembled a world-class, cross-disciplinary team of recognized scientists, clinicians, and drug developers to tackle devastating ocular and systemic degenerative, fibrotic, and...